Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Asset Utilization Ratio (2026)

Updated

Aktis Oncology's (AKTS) Asset Utilization Ratio came in at 0.02 for Q3 2026, up 28.1% from the prior quarter.

Analysis

Aktis Oncology (AKTS) Asset Utilization Ratio (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 0.60
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 0.50
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 0.47
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 0.51
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 0.50
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 0.41
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 0.62
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 0.31
10 Aktis Oncology 895.95 Mn 335.72 Mn - 0.02
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 0.02
Jun 30, 2026 0.02
API Access

Aktis Oncology Asset Utilization Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-utilization-ratio&ticker=AKTS&period=max&api_key=YOUR_API_KEY